Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2015

Published: Nov, 2015 | Pages: 216 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2015', provides an overview of the Gastrointestinal Stromal Tumor (GIST)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastrointestinal Stromal Tumor (GIST) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gastrointestinal Stromal Tumor (GIST) Overview 10
Therapeutics Development 11
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview 11
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis 12
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies 13
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes 15
Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies 19
Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes 21
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 22
AB Science SA 22
Advenchen Laboratories, LLC 23
Ariad Pharmaceuticals, Inc. 24
Arog Pharmaceuticals, Inc. 25
Array BioPharma Inc. 26
Astex Pharmaceuticals, Inc. 27
Blueprint Medicines 28
Boston Biomedical, Inc. 29
Calithera Biosciences, Inc. 30
Chipscreen Biosciences Ltd 31
Deciphera Pharmaceuticals, LLC 32
F. Hoffmann-La Roche Ltd. 33
Immunicum AB 34
Jiangsu Hengrui Medicine Co., Ltd. 35
Natco Pharma Limited 36
Nerviano Medical Sciences S.r.l. 37
Novartis AG 38
Omeros Corporation 39
Plexxikon Inc. 40
Synta Pharmaceuticals Corp. 41
Takeda Pharmaceutical Company Limited 42
TG Therapeutics, Inc. 43
Threshold Pharmaceuticals, Inc. 44
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Target 47
Assessment by Mechanism of Action 50
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
alpelisib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
apatinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BBI-503 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
binimetinib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BLU-285 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
buparlisib hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
CB-839 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
crenolanib besylate - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
CS-2164 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
DCC-2618 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
evofosfamide - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ganetespib - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Intuvax - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
masitinib - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
motesanib diphosphate - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
nilotinib - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
NMSP-088 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
NRCAN-019 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
onalespib - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
pexidartinib - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
PLX-9486 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
ponatinib hydrochloride - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
SF-1126 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
SHR-1020 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
TGR-1202 - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
vemurafenib - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Gastrointestinal Stromal Tumor (GIST) - Recent Pipeline Updates 135
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 205
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 206
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 207
Featured News & Press Releases 207
Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285 207
Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets 207
Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting 208
Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors 208
Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican 209
Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig 210
Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors 211
Jun 02, 2013: Threshold Pharma Announces Data From Two Ongoing Phase I/II Trials Of TH-302 At 2013 ASCO Annual Meeting 212
Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors 213
Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At AACR Annual Meeting 214
Appendix 215
Methodology 215
Coverage 215
Secondary Research 215
Primary Research 215
Expert Panel Validation 215
Contact Us 215
Disclaimer 216

List of Tables

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2015 11
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2015 22
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories, LLC, H2 2015 23
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015 24
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals, Inc., H2 2015 25
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc., H2 2015 26
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 27
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines, H2 2015 28
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical, Inc., H2 2015 29
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences, Inc., H2 2015 30
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H2 2015 31
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015 32
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 33
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H2 2015 34
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015 35
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H2 2015 36
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015 37
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H2 2015 38
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corporation, H2 2015 39
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H2 2015 40
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Synta Pharmaceuticals Corp., H2 2015 41
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 42
Gastrointestinal Stromal Tumor (GIST) - Pipeline by TG Therapeutics, Inc., H2 2015 43
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 44
Assessment by Monotherapy Products, H2 2015 45
Assessment by Combination Products, H2 2015 46
Number of Products by Stage and Target, H2 2015 48
Number of Products by Stage and Mechanism of Action, H2 2015 51
Number of Products by Stage and Route of Administration, H2 2015 54
Number of Products by Stage and Molecule Type, H2 2015 56
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Recent Pipeline Updates, H2 2015 135
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2015 205
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2015 206